Foco cáncer de pulmón y oncologÃa gastrointestinal
Foco cáncer de pulmón y oncologÃa gastrointestinal
Foco cáncer de pulmón y oncologÃa gastrointestinal
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Erlo2nib showed overall survival advantage in <br />
pre-‐treated NSCLC (BR.21) <br />
100 <br />
Erlo@nib <br />
(n=488) <br />
Placebo <br />
(n=243) <br />
Survival probability (%) <br />
75 <br />
50 <br />
25 <br />
Median survival (months) 6.7 4.7 <br />
HR=0.73 (0.60–0.87), p=0.001* <br />
27% reduc@on in risk of <strong>de</strong>ath with erlo@nib <br />
42.5% increase in median survival with erlo@nib <br />
0 <br />
0 5 10 15 20 25 30 <br />
Survival @me (months) <br />
*Adjusted for stra@fica@on factors <br />
(except centre) and EGFR status <br />
Shepherd, et al. NEJM 2005 <br />
Tarceva SmPC
Change language